Amendment of Solicitation/modification of Contract 1. Contract Id Code Page of Pages

Exhibit 10.2

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Section B –** Supplies or Services and Prices/Costs**

Article B.2 Base Period is deleted and replaced as follows:

Article G.2. CONTRACTING OFFICER'S REPRESENTATIVE

The following Contracting Officer's Representative (COR) will represent the Government for the purpose of this contract:

Primary Contracting Officer's Representative (COR)

Olivia Molinar-Inglis

Contracting Officer's Representative

Center for the Biomedical Advanced Research and Development Authority (BARDA)

Office of the Assistant Secretary for Preparedness and Response

Department of Health and Human Services

Email: Oliva.Molinar-Inglis@hs.gov

Phone: (202) 205-2820

***Alternate Contracting Officer's Representative (ACOR) ***

Christina Son

Alternate Contracting Officer's Representative (ACOR)

Center for the Biomedical Advanced Research and Development Authority (BARDA)

Office of the Assistant Secretary for Preparedness and Response

Department of Health and Human Services

Email: Christina.Son@hhs.gov

Phone: (202) 692-4621

The COR is responsible for:

a.    Monitoring the Contractor's technical progress, including the surveillance and assessment of performance, and recommending to the Contracting Officer changes in requirements.

b.    Assisting the Contracting Officer in interpreting the statement of work and any other technical performance requirements.

c.    Performing technical evaluation as required.

d.    Performing technical inspections and assisting the Contracting Officer in acceptance of
deliverables required by this contract.

e.    Assisting in the resolution of technical problems encountered during performance.

f.    The Government may unilaterally change its COR designation(s).

Article G.4 KEY PERSONNEL

The following Key Personnel will represent the Contractor for the purpose of this contract:

The key personnel specified in this contract are considered to be essential to work performance. At least 30 days prior to the contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the contractor is terminated for cause or separates from the contractor voluntarily with less than thirty (30) days' notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.

The following individual(s) is/are considered to be essential to the work being performed hereunder:

Section J –** List of Attachments, Attachment 2, Statement of Work is deleted and replaced as follows:**

Contract HHSO100201800019C
Modification 0019
Statement of Work

The scope of this proposal includes the following activities:

1.1. CLIN0001 (Contract mod 0018): Tech transfer of previously completed GMP manufacturing to new facility, material procurement, engineering and process validation batches, regulatory, labor, shipping of final deliverable to SNS

Deliverable: Process validation batches

1.2. CLIN0001 (Contract mod 0019 This contract mod): Completion of remaining CMC, Clinical, and Regulatory tasks in support of NDA filing for the Pediatric Oral Suspension formulation including manufacture of process validation batches, clinical study conduct, application submission to FDA, labor, and shipping of the process validation batches to the SNS

Deliverable: Process validation batches

1.3. CLIN0001 (This contract mod): Regulatory document compilation, writing, reviewing, submission, and responses to FDA questions applicable to removal of all dyes from the TPOXX capsules. Note that SIGA retains ownership of the TPOXX capsule batches manufactured for this purpose.

Procurement of [***] treatment courses of BDS for the manufacturing of IV TPOXX}

7.1 CLIN 0007 (Contract mod 003): Pediatric formulation pharmacokinetic clinical study protocol, pharmacokinetic study in subjects weighting more than 120 kg protocol, pediatric formulation SAD Study protocol and start-up, start-up pediatric formulation development, labor

The objectives of this modification are:

The final deliverable is:

Detailed Breakdown of the activities funded under CLIN 0001 in this modification:

1.         Consultant support

2.         SIGA labor

All other terms and conditions of this contract remain unchanged and in full force and effect.

END OF MODIFICATION P00020 to HHSO100201800019C